K-41
K-41 is an orally active antibiotic. K-41 can be obtained from Streptomyces hygroscopicus. K-41 has antibacterial and antiplasmodial activity.
For research use only. We do not sell to patients.
- CAS No.: 53026-37-2
- Formula: C48H82O18
- Molecular Weight:947.15
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
-
HY-N0402S
Artemether-d3Stable Isotope -
HY-G0016
N-Acetyl dapsoneDapsone Metabolite -
HY-N3300
MelleinNatural Product -
HY-124452
NocardamineSiderophore -
HY-N1584B
Halofuginone hydrochlorideNatural Product -
HY-W196368
ThymohydroquinoneCOX-2 Inhibitor -
HY-125049
KijanimicinAntibiotic -
HY-N7536
VoacangineTRPM8 Antagonist -
HY-113784
ThiocarlideAntibacterial Agent -
HY-N8373
Beauvericin AAntibacterial Agent -
HY-N1584BR
Halofuginone hydrochloride (Standard)Reference Standard -
HY-123635
NybomycinAntibiotic
Biological Activity
Description
In Vitro
K-41 inhibits K1 and FCR3 strains of Plasmodium falciparum, with IC50s of 8.5 and 31 nM[1].
K-41 inhibits B. subtilis, B. anthracis, S. aureus, S. pyogenes, S. pneumonia, C. diphtheria, and M. tuberculosis, with MICs of 3.13, 1.56, 1.56, 0.78, 0.39, 0.78, and 3.13 µg/mL, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Chemical Information
-
CAS No. 53026-37-2
-
Molecular Weight 947.15
-
Formula C48H82O18
-
SMILES
C[C@H]([C@H]1OC)[C@](O[C@@H](C2)C[C@H](O[C@]3(O)[C@@H](O)C(O)=O)[C@@](C)([C@H]([C@@H]3C)OC)OC)([C@@H]([C@@H]2OC)C)O[C@@]1([C@]4([H])O[C@@]([C@]5([H])O[C@]([C@](O[C@@]6(O)C)([H])[C@H]([C@@H]([C@H]6C)O[C@@H](CC[C@@H]7OC)O[C@@H]7C)C)([H])CC5)([H])CC4)C
-
Structure Classification
-
Initial Source
germ
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Purity & Documentation
References
[1]. Otoguro K, et al. In vitro and in vivo antimalarial activities of the monoglycoside polyether antibiotic, K-41 against drug resistant strains of Plasmodia. J Antibiot (Tokyo). 2002 Sep;55(9):832-4. [Content Brief]
[2]. Tsuji N, et al. Two new antibiotics, A-218 and K-41. Isolation and characterization. J Antibiot (Tokyo). 1976 Jan;29(1):10-4. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
K-41 Related Classifications
HY-136943 Related Classifications
Powered by Bioz